Pharmacovigilance - Volume 2 2023
DOI: 10.5772/intechopen.105504
|View full text |Cite
|
Sign up to set email alerts
|

Early Signal Detection: Data Mining of Mental Disorders with Statins

Abstract: Statins are widely prescribed to treat dyslipidemias. It is well-known adverse reaction of these active ingredients related to rhabdomyolysis and myalgia, but there are other signals to be aware of, such as mental disorders. Pharmacovigilance tools help to trace known risks and detect early other unknown effects that appear over time. Data of all the reported suspected adverse drug reactions for statins from the international World Health Organization (WHO) repository Vigibase were analyzed with an adaptation … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 44 publications
0
0
0
Order By: Relevance
“…In this database, it is plausible to approach the frequency of suspected ADR using the data mining methodology developed and is used by de UMC as the WHO Collaborating Centre for International Drug Monitoring that is Bayesian Confidence Propagation Neural Network (BCPNN) [8], extensions [9][10][11][12][13] and adaptations with a correct interpretation of the signals [14][15][16][17][18].…”
Section: What Motor Disorders Are Candidatesmentioning
confidence: 99%
See 1 more Smart Citation
“…In this database, it is plausible to approach the frequency of suspected ADR using the data mining methodology developed and is used by de UMC as the WHO Collaborating Centre for International Drug Monitoring that is Bayesian Confidence Propagation Neural Network (BCPNN) [8], extensions [9][10][11][12][13] and adaptations with a correct interpretation of the signals [14][15][16][17][18].…”
Section: What Motor Disorders Are Candidatesmentioning
confidence: 99%
“…In this case, the chemical subgroup C10AA "HMG CoA reductase inhibitors" [15] was considered in the analysis. This adaptation was previously applied and approved robustness and consistency with other specific groups of drugs [16][17][18].…”
Section: Conflict Of Interestmentioning
confidence: 99%